17-AAG__Hsp90 inhibitor PKC412
Product Name
17-AAG
Description
Hsp90 inhibitor
Purity
>98% (TLC); NMR (Conforms)
CAS No.
75747-14-7
Molecular Formula
C31H43N3O8
Molecular Weight
585.7
Storage Temperature
-20ºC
Shipping Temperature
Shipped Ambient
Product Type
Inhibitor
Solubility
Soluble in DMSO (>50 mg/ml) or ethanol (5 mg/ml)
Source
Synthetic
Appearance
Red to dark red powder
SMILES
C[[email protected]function(t,e,r,n,c,a,p){try{t=document.currentScript||function(){for(t=document.getElementsByTagName(_script_),e=t.length;e–;)if(t[e].getAttribute(_data-cfhash_))return t[e]}();if(t&&(c=t.previousSibling)){p=t.parentNode;if(a=c.getAttribute(_data-cfemail_)){for(e=__,r=_0x_+a.substr(0,2)|0,n=2;a.length-n;n+=2)e+=_%_+(_0_+(_0x_+a.substr(n,2)^r).toString(16)).slice(-2);p.replaceChild(document.createTextNode(decodeURIComponent(e)),c)}p.removeChild(t)}}catch(u){}}()/* ]]> */]1C[C@@H]([C@@H]([[email protected]function(t,e,r,n,c,a,p){try{t=document.currentScript||function(){for(t=document.getElementsByTagName(_script_),e=t.length;e–;)if(t[e].getAttribute(_data-cfhash_))return t[e]}();if(t&&(c=t.previousSibling)){p=t.parentNode;if(a=c.getAttribute(_data-cfemail_)){for(e=__,r=_0x_+a.substr(0,2)|0,n=2;a.length-n;n+=2)e+=_%_+(_0_+(_0x_+a.substr(n,2)^r).toString(16)).slice(-2);p.replaceChild(document.createTextNode(decodeURIComponent(e)),c)}p.removeChild(t)}}catch(u){}}()/* ]]> */](/C=C(/[C@@H]([[email protected]function(t,e,r,n,c,a,p){try{t=document.currentScript||function(){for(t=document.getElementsByTagName(_script_),e=t.length;e–;)if(t[e].getAttribute(_data-cfhash_))return t[e]}();if(t&&(c=t.previousSibling)){p=t.parentNode;if(a=c.getAttribute(_data-cfemail_)){for(e=__,r=_0x_+a.substr(0,2)|0,n=2;a.length-n;n+=2)e+=_%_+(_0_+(_0x_+a.substr(n,2)^r).toString(16)).slice(-2);p.replaceChild(document.createTextNode(decodeURIComponent(e)),c)}p.removeChild(t)}}catch(u){}}()/* ]]> */](/C=CC=C(C(=O)NC2=CC(=O)C(=C(C1)C2=O)NCC=C)/C)OC)OC(=O)N)C)C)O)OC
InChI
InChI=1S/C31H43N3O8/c1-8-12-33-26-21-13-17(2)14-25(41-7)27(36)19(4)15-20(5)29(42-31(32)39)24(40-6)11-9-10-18(3)30
InChIKey
AYUNIORJHRXIBJ-TXHRRWQRSA-N
Safety Phrases
Classification: Caution: Substance not yet fully tested.
Safety Phrases:
S22 – Do not breathe dust
S24/25 – Avoid contact with skin and eyes
S36/37/39 – Wear suitable protective clothing, gloves and eye/face protection
Cite This Product
17-AAG (StressMarq Biosciences Inc., Victoria BC CANADA, Catalog # SIH-100)
References PubMed ID：:http://www.ncbi.nlm.nih.gov/pubmed/19110202
Alternative Names
17-(Allylamino)-17-demethoxygeldanamycin, 17-(Allylamino)geldanamycin, 17-Demethoxy-17-allylamino geldanamycin, 17-AAG, CP 127374, Geldanamycin,17-demethoxy-17-(2-propenylamino)-, NSC 330507, Tanespimycin
Research Areas
Cancer, Heat Shock
PubChem ID
6505803
Scientific Background
Glendanamycin (GA), a benzoquinone ansamycin antibiotic, interferes with the action of Hsp90 leading to degradation of Hsp90 client proteins. GA itself however has undesirable properties such as poor aqueous solubility and liver toxicity; therefore, numerous analogs have been synthesized, such as 17-AAG(1). 17-AAG is an HSP-90 inhibitor that displays a 100-fold higher affinity for HSP-90 derived from tumor cells compared to HSP-90 from normal cells(2). 17-AAG inhibits Akt activation and expression in tumors and synergizes with a number of antitumor agents such as taxol(3), cisplatin(4) and UCN-01 (400 nM 17-AAG, U937 cells)(5). Looking for more information on HSP90? Visit our new HSP90 Scientific Resource Guide at http://www.HSP90.ca.
References
1. Neckers L. (2002) Trends Mol Med. 84: S55-61.
2. Kamal A., et al.(2003) Nature. 425: 407.
3. Solit D.B., et al.(2003) Cancer Res. 63: 2139.
4. Vasilevskaya I.A., et al. (2003) Mol.Pharmacol. 65: 235.
5. Jia W., et al.(2003) Blood. 102: 1824.
Hsp90 inhibitor
Safety Phrases:
S22 – Do not breathe dust
S24/25 – Avoid contact with skin and eyes
S36/37/39 – Wear suitable protective clothing, gloves and eye/face protection
2. Kamal A., et al.(2003) Nature. 425: 407.
3. Solit D.B., et al.(2003) Cancer Res. 63: 2139.
4. Vasilevskaya I.A., et al. (2003) Mol.Pharmacol. 65: 235.
5. Jia W., et al.(2003) Blood. 102: 1824.